Functional antibody response to human cytomegalovirus in immunocompetent and HIV-1 infected individuals with antibodies that inhibit virus penetration into cells and intercellular transmission of viral infection

Journal of Medical Microbiology

Volumn 48, Issue 10, 1999, Pages 947-954

  Alberola, J ^a   Tamarit, A ^a   Navarro, D ^a  

^a UNIVERSITY OF VALENCIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOMEGALOVIRUS ANTIBODY; NEUTRALIZING ANTIBODY;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CELL FUSION; CELL SPREADING; CLINICAL ARTICLE; CYTOMEGALOVIRUS INFECTION; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN CYTOMEGALOVIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOCOMPETENCE; MALE; NONHUMAN; PRIORITY JOURNAL; VIRUS ADSORPTION; VIRUS CELL INTERACTION; VIRUS NEUTRALIZATION; VIRUS TRANSMISSION;

EID: 0032741378     PISSN: 00222615     EISSN: None     Source Type: Journal    
DOI: 10.1099/00222615-48-10-947     Document Type: Article

References (30)

1. Drew WL. Cytomegalovirus infection in patients with AIDS. Clin Infect Dis 1992; 14: 608-615.
2. Boppana SB, Pass RF, Britt WJ. Virus-specific antibody responses in mothers and their newborn infants with asymptomatic congenital cytomegalovirus infections. J Infect Dis 1993; 167: 72-77.
3. Jonjić S, Pavić I, Polić B, Crnković I, Lućín P, Koszinowski UH. Antibodies are not essential for the resolution of primary Cytomegalovirus infection but limit dissemination of recurrent virus. J Exp Med 1994; 179: 1713-1717.
4. Boppana SB, Britt WJ. Antiviral antibody responses and intrauterine transmission after primary maternal Cytomegalovirus infection. J Infect Dis 1995; 171: 1115-1121.
5. Boppana SB, Polis MA, Kramer AA, Britt WJ, Koenig S. Virus-specific antibody responses to human Cytomegalovirus (HCMV) in human immunodeficiency virus type I-infected persons with HCMV retinitis. J Infect Dis 1995; 171: 182-185.
6. Alberola J, Dominguez V, Cardeñoso L et al. Antibody response to Human Cytomegalovirus (HCMV) glycoprotein B(gB) in AIDS patients with HCMV end-organ disease. J Med Virol 1998; 55: 272-280.
7. Dimmock NJ. Update on the neutralisation of animal viruses. Rev Med Virol 1995; 5: 165-179.
8. Navarro D, Paz P, Tugizov S, Topp K, La Vail J, Pereira L. Glycoprotein B of human cytomegalovirus promotes virion penetration into cells, the transmission of infection from cell to cell and fusion of infected cells. Virology 1993; 197: 143-158.
9. Pereira L. Function of glycoprotein B homologues of the family Herpesviridae. Infect Agents Dis 1994; 3: 9-28.
10. Tugizov S, Navarro D, Paz P, Wang Y, Qadri I, Pereira L. Function of human cytomegalovirus glycoprotein B: syncytium formation in cells constitutively expressing gB is blocked by virus-neutralizing antibodies. Virology 1994; 201: 263-276.
11. Tugizov S, Wang Y, Qadri I, Navarro D, Maidji E, Pereira L. Mutated forms of human cytomegalovirus glycoprotein B are impaired in inducing syncytium formation. Virology 1995; 209: 580-591.
12. Pereira L, Lennette E, Paz P. Navarro D. Humoral immunity to glycoprotein B in primary and recurrent human cytomegalovirus infections. In: Landini MP (ed) Progress in cytomegalovirus research. Amsterdam, Elsevier Science Publishers. 1993: 145-148.
13. Navarro D, Lennette E, Tugizov S, Pereira L. Humoral immune response to functional regions of human cytomegalovirus glycoprotein B. J Med Virol 1997; 52: 451-459.
14. Lutch E, Sundqvist V-A, Linde A et al. Presence of autologous neutralizing antibodies against cytomegalovirus (CMV) in serum of human immunodeficiency virus type I-infected patients shedding CMV in saliva. J Infect Dis 1994; 169: 1096-1100.
15. Rasmussen L, Morris S. Wolitz R et al. Deficiency in antibody response to human cytomegalovirus glycoprotein gH in human immunodeficiency virus-infected patients at risk for cytomegalovirus retinitis. J Infect Dis 1994; 170: 673-677.
16. Thomas LH, Cook RS, Wyld SG, Furze JM, Taylor G. Passive protection of gnotobiotic calves using monoclonal antibodies directed at different epitopes on the fusion protein of bovine respiratory syneytial virus. J Infect Dis 1998; 177: 874-880.
17. Mocarski ES, Bonyhadi M, Salimi S, McCune JM, Kaneshima H. Human cytomegalovirus in a SCID-hu mouse: thymic epithelial cells are prominent targets of viral replication. Proc Natl Acad Sci USA 1993; 90: 104-108.
18. Gea-Banacloche JC, Weiskopf EE, Hallahan C et al. Progression of human immunodeficiency virus disease is associated with increasing disruptions within the CD4+ T cell receptor repertoire. J Infect Dis 1998; 177: 579-585.
19. Virgin HW, Bassel-Duby R, Fields BN, Tyler KL. Antibody protects against lethal infection with the neurally spreading reovirus type 3 (Dearing). J Virol 1988; 62: 4594-4604.
20. Cremer NE, Cossen CK, Shell GR, Pereira L. Antibody response to cytomegalovirus polypeptides captured by monoclonal antibodies on the solid phase in enzyme immunoassays. J Clin Microbiol 1985; 21: 517-521.
21. Gonezol E, Hudeez F, Ianacone J, Dietzschold B, Starr S, Plotkin SA. Immune responses to isolated human cytomegalovirus envelope proteins. J Virol 1986; 58: 661-664.
22. Rasmussen L, Matkin C, Spaete R, Pachl C. Merigan TC. Antibody response to human cytomegalovirus glycoproteins gB and gH after natural infection in humans. J Infect Dis 1991; 164: 835-842.
23. Qadri I, Navarro D, Paz P, Pereira L. Assembly of conformation-dependent neutralizing domains on glycoprotein B of human Cytomegalovirus. J Gen Virol 1992; 73: 2913-2921.
24. Britt WJ, Vugler L, Stephens EB. Induction of complement-dependent and -independent neutralizing antibodies by recombinant-derived human cytomegalovirus gp55-116 (gB). J Virol 1988; 62: 3309-3318.
25. Britt WJ, Vugler L, Butfiloski EJ. Stephens EB, Cell surface expression of human cytomegalovirus (HCMV) gp55-116 (gB): use of HCMV-recombinant vaccinia virus-infected cells in analysis of the human neutralizing antibody response. J Virol 1990; 64: 1079-1085.
26. Gonczol E, Ianacone J, Ho W, Starr S, Meignier B, Plotkin S. Isolated gA/gB glycoprotein complex of human cytomegalovirus envelope induces humoral and cellular immune-responses in human volunteers. Vaccine 1990; 8: 130-136.
27. Marshall GS, Rabalais GP, Stout GG, Waldeyer SL. Antibodies to recombinant-derived glycoprotein B after natural human cytomegalovirus infection correlate with neutralizing activity. J Infect Dis 1992; 165: 381-384.
28. Marshall GS, Stout GG, Knights ME et al. Ontogeny of glycoprotein gB-specific antibody and neutralizing activity during natural cytomegalovirus infection. J Med Virol 1994; 43: 77-83.
29. Urban M, Klein M, Britt WJ, Hassfurther E, Mach M. Glycoprotein H of human cytomegalovirus is a major antigen for the neutralizing humoral immune response. J Gen Virol 1996; 77: 1537-1547.
30. Milne RSB, Paterson DA, Booth JC. Human cytomegalovirus glycoprotein H/glycoprotein L complex modulates fusion-from-without. J Gen Virol 1998; 79: 855-865.